NEWS
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech firm, will present significant research at the Psychedelic Medicine – Israel 2024 conference in Tel Aviv from July 28-30. CEO Adi Zullof-Shani, Ph.D., will discuss the potential of 5-Methoxy-2-Aminoindane (MEAI) as a regulator of binge behaviors on July 29. Additionally, researchers Prof. Joseph Tam and Dr. Saja Baraghithy will present a study on MEAI's effects on diet-induced obesity on July 30. Their findings indicate MEAI's promise in reducing obesity and improving metabolic health. The conference aims to advance psychedelic medicine through international collaboration and research dissemination.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1170Followers
73Following
8177Visitors
Follow